Methylome Analysis in Nonfunctioning and GH-Secreting Pituitary Adenomas.
GH-OMAs
NFPAs
methylation
pituitary adenomas
pituitary tumors
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
12
2021
accepted:
21
02
2022
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
20
4
2022
Statut:
epublish
Résumé
Pituitary adenomas (PAs), usually benign lesions, can sometimes present with "aggressive" features (rapid growth, local invasiveness, scarce response to conventional treatments). Despite the fact that a few genetic alterations have been associated to this clinical behavior, the role of epigenetic modifications, mainly methylation and miRNAs activity, is now opening new frontiers in this field. We evaluated the methylation profile of 21 PA (11 GH-omas, 10 nonfunctioning tumors-NFPAs) samples from TNS surgery and 5 normal pituitaries, collected at our neurosurgery between 2015 and 2017. DNA was extracted and sequenced, selecting 184,841 target regions. Moreover, methylation profiles were correlated with demographic, radiological, and clinicopathological features. NFPAs showed higher methylation levels vs. GH-omas, with 178 differentially methylated regions (DMRs) mainly consisting of noncoding and intronic sequences, and mostly localized in the open sea regions. We also found three hypermethylated genes (
Identifiants
pubmed: 35432200
doi: 10.3389/fendo.2022.841118
pmc: PMC9007725
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
841118Informations de copyright
Copyright © 2022 Giuffrida, D’Argenio, Ferraù, Lasorsa, Polito, Aliquò, Ragonese, Cotta, Alessi, Oteri, Di Maggio, Asmundo, Romeo, Spagnolo, Pastore, Angileri, Capasso, Cannavò and Aguennouz.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Endocrinol (Lausanne). 2019 May 14;10:290
pubmed: 31139150
Bioinformatics. 2015 Apr 1;31(7):1130-2
pubmed: 25417205
N Engl J Med. 2020 Mar 5;382(10):937-950
pubmed: 32130815
Endocr Connect. 2019 May 1;8(5):528-535
pubmed: 30939449
World Neurosurg. 2020 May;137:252-256
pubmed: 31678448
J Appl Genet. 2012 May;53(2):167-74
pubmed: 22183866
J Endocrinol Invest. 2020 Jul;43(7):947-958
pubmed: 31939196
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
J Cell Physiol. 2019 Nov;234(11):20002-20012
pubmed: 30945310
Med Sci Monit. 2018 Jul 13;24:4841-4850
pubmed: 30002361
J Clin Endocrinol Metab. 2016 Apr;101(4):1872-9
pubmed: 26963951
PLoS One. 2014 Apr 29;9(4):e96178
pubmed: 24781529
J Clin Endocrinol Metab. 2018 Mar 23;:
pubmed: 29590371
Endocr Rev. 2020 Dec 1;41(6):
pubmed: 32201880
Oncol Rep. 2017 Aug;38(2):1140-1148
pubmed: 28656268
J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011
pubmed: 22723327
J Endocrinol Invest. 2018 May;41(5):575-581
pubmed: 29080965
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2892-2902
pubmed: 30869797
Mol Cell Endocrinol. 2017 Dec 5;457:81-88
pubmed: 27998805
PLoS One. 2013 Dec 18;8(12):e82619
pubmed: 24367530
Eur J Endocrinol. 2010 Oct;163(4):509-13
pubmed: 20621957
Neurobiol Learn Mem. 2018 Nov;155:239-248
pubmed: 30099202
Mol Cell Biol. 2003 Mar;23(6):1843-55
pubmed: 12612060
Am J Pathol. 2012 Apr;180(4):1495-508
pubmed: 22326833
Clin Endocrinol (Oxf). 2014 Aug;81(2):249-53
pubmed: 24521362
Front Endocrinol (Lausanne). 2021 Jan 26;11:596554
pubmed: 33574795
Front Endocrinol (Lausanne). 2020 Nov 12;11:591039
pubmed: 33281746
Endocr Relat Cancer. 2012 Nov 19;19(6):805-16
pubmed: 23045325
Eur J Endocrinol. 2020 Dec;183(6):597-606
pubmed: 33075752
Eur J Endocrinol. 2018 Jan;178(1):G1-G24
pubmed: 29046323
Endocr Rev. 2009 Jun;30(4):293-342
pubmed: 19502515
J Neurooncol. 2016 Aug;129(1):23-31
pubmed: 27168190
Cancers (Basel). 2020 Feb 22;12(2):
pubmed: 32098443
J Clin Endocrinol Metab. 2008 Oct;93(10):4119-25
pubmed: 18628527